MedTrace Logo

Polyglucosamine L112 in Overweight and Obese Subjects

NCT05022732 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2021-08-26

No results posted yet for this study

Summary

This research proposes as its main purpose to evaluate the effectiveness of the intake of Polyglucosamine at a dose of 3 g / day on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 kg / m2). and with weight\> 75 kg

Conditions

Interventions

DIETARY_SUPPLEMENT

Polyglucosamine L112

750 mg of chitosan for tablet formulated with ascorbic acid and tartaric acids in the relative proportions of 91-6-3% with the addition of formulating excipients

COMBINATION_PRODUCT

Placebo

excipients and gum arabic

Sponsors & Collaborators

  • Azienda di Servizi alla Persona di Pavia

    lead OTHER

Principal Investigators

  • Mariangela Rondanelli · Fondazione Casemiro Mondino

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-05-05
Primary Completion
2020-08-05
Completion
2021-08-19

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05022732 on ClinicalTrials.gov